CASE REPORT
Published on 11 Dec 2025
Case report of acute hepatorenal failure induced by third-line treatment with tislelizumab in a patient with cholangiocarcinoma: was influenza virus the culprit?
doi 10.3389/fimmu.2025.1631953
- 189 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Advancements in Antibody-Based Immunotherapy and Cancer Vaccines for Hepatocellular Carcinoma
Advancements in Antibody-Based Immunotherapy and Cancer Vaccines for Hepatocellular Carcinoma
7,154
Total downloads
30k
Total views and downloads
Articles
EDITORIAL
Accepted on 09 Dec 2025
Editorial: Advancements in Antibody-Based Immunotherapy and Cancer Vaccines for Hepatocellular Carcinoma
CASE REPORT
Published on 11 Sep 2025
Atezolizumab-induced vanishing bile duct syndrome: a case report
doi 10.3389/fonc.2025.1637847
- 1,295 views
- 1 citation
ORIGINAL RESEARCH
Published on 17 Jul 2025
Postoperative hepatitis B virus reactivation and its impact on survival in HBV-related hepatocellular carcinoma patients undergoing conversion therapy with interventional therapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors
doi 10.3389/fcimb.2025.1598193
- 2,039 views
REVIEW
Published on 20 Jun 2025
Antibody treatment of hepatocellular carcinoma: a review of current and emerging approaches
doi 10.3389/fimmu.2025.1533874
- 3,516 views
ORIGINAL RESEARCH
Published on 05 Jun 2025
Dissecting the multi-omics landscape of TEAD1 in hepatocellular carcinoma: cycle regulation and metastatic potential
doi 10.3389/fimmu.2025.1567969
- 1,950 views
- 1 citation
ORIGINAL RESEARCH
Published on 08 May 2025
A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTEFAP5/CD3, CAR-T cells, and immunotoxins in hepatocellular carcinoma
doi 10.3389/fimmu.2025.1509087
- 3,113 views
ORIGINAL RESEARCH
Published on 10 Dec 2024
Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab
doi 10.3389/fimmu.2024.1506355
- 2,639 views
- 4 citations
ORIGINAL RESEARCH
Published on 23 Oct 2024
Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
doi 10.3389/fimmu.2024.1491857
- 2,731 views
- 2 citations
SYSTEMATIC REVIEW
Published on 02 Aug 2024
Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis
doi 10.3389/fimmu.2024.1421520
- 3,393 views
- 4 citations
ORIGINAL RESEARCH
Published on 26 Jul 2024
TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study
doi 10.3389/fimmu.2024.1430571
- 3,159 views
- 10 citations
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Other participating journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore